Table 1.
Ref. | Country | Participants | Intervention | Duration of follow-up | Results |
Forman et al[43] | United States | 283 African-American | Oral vitamin D3 (cholecalciferol, 1000, 2000, or 4000 IU), or placebo per day for 3 mo | 6 mo | Reduction in systolic pressure. |
subjects | |||||
Harris et al[44] | United States | 45 African-American adults | 60000 IU monthly oral vitamin D(3) or placebo for 16 wk | 16 wk | Effective at improving vascular endothelial function |
Larsen et al[45] | Denmark | 112 Hypertensive patients | 75 µg (3000 IU) cholecalciferol per day or placebo for 20 wk | 20 wk | Significant decreases in systolic blood pressure |
Lind et al[46] | Sweden | 65 subjects with impaired glucose tolerance | Alphacalcidol (0.75 microgram daily) or placebo over 12 wk | 12 wk | Significant reduction of blood pressure |
Lind et al[47] | Sweden | 65 Hypertensive patients with primary hyperparathyroidism | Alphacalcidol, (1 microgram daily) or placebo over 6 mo | 6 mo | Significant reduction of blood pressure |
Longenecker et al[48] | United States | 45 HIV-infected individuals with vitamin D deficiency | Vitamin D3 4000 IU daily or placebo for 12 wk | 12 wk | Modestly improved cholesterol |
Salehpour et al[49] | Iran. | 77 healthy premenopausal overweight and obese women | Vitamin D (25 μg/d as cholecalciferol) or the placebo group for 12 wk | 12 wk. | Significantly improvement of HDL-cholesterol, apoA-I |
concentrations and LDL-cholesterol:apoB-100 ratio. | |||||
Shedeed[50] | Egypt | 80 infants with CHF | Vitamin D(3) oral drops or placebo oral drops for 12 wk | 12 wk | Significant improvement of HF score, LV end-diastolic diameter, LV end-systolic diameter, LV ejection fraction%, and myocardial performance index. |
Witham et al[51] | United Kingdom | 58 stroke patients | 100000 units of a single oral dose of vitamin D2 or placebo | 16 wk | Short-term improvement in endothelial function (Flow mediated dilatation was significantly higher in the intervention group at 8 wk) |
Zittermann et al[52] | Germany | 200 healthy overweight subjects in a weight-reduction program | Vitamin D (83 microg/d) or placebo for 12 mo | 12 mo | Significant improvement of cardiovascular disease risk markers |
LV: Left-ventricular; CHF: Congestive heart failure; HDL: High-density lipoprotein; LDL: Low-density lipoprotein; IU: International units.